MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- BIOCON - ACTAVIS (US)
BIOCON vs ACTAVIS (US) - Comparison Results
BIOCON Change
Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 BIOCON  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| BIOCON Mar-19 |
ACTAVIS Dec-18 |
BIOCON / ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 707 | 14,011 | - | |
| Low | Rs | 554 | 9,399 | - | |
| Sales per share (Unadj.) | Rs | 91.9 | 3,437.0 | - | |
| Earnings per share (Unadj.) | Rs | 16.7 | -1,107.1 | - | |
| Cash flow per share (Unadj.) | Rs | 24.2 | 362.2 | - | |
| Dividends per share (Unadj.) | Rs | 1.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 101.6 | 14,175.9 | - | |
| Shares outstanding (eoy) | m | 600.00 | 332.60 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 6.9 | 3.4 | 201.5% | |
| Avg P/E ratio | x | 37.7 | -10.6 | -356.9% | |
| P/CF ratio (eoy) | x | 26.1 | 32.3 | 80.7% | |
| Price / Book Value ratio | x | 6.2 | 0.8 | 751.4% | |
| Dividend payout | % | 6.0 | 0 | - | |
| Avg Mkt Cap | Rs m | 378,330 | 3,893,108 | 9.7% | |
| No. of employees | `000 | 6.1 | 16.9 | 36.3% | |
| Total wages/salary | Rs m | 11,653 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,994.3 | 67,641.2 | 13.3% | |
| Avg. wages/employee | Rs Th | 1,900.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,635.3 | -21,787.3 | -7.5% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 55,144 | 1,143,137 | 4.8% | |
| Other income | Rs m | 1,444 | 21,861 | 6.6% | |
| Total revenues | Rs m | 56,588 | 1,164,997 | 4.9% | |
| Gross profit | Rs m | 15,883 | 29,956 | 53.0% | |
| Depreciation | Rs m | 4,478 | 488,666 | 0.9% | |
| Interest | Rs m | 709 | 65,966 | 1.1% | |
| Profit before tax | Rs m | 12,140 | -502,815 | -2.4% | |
| Minority Interest | Rs m | 9 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 128,238 | 0.0% | |
| Tax | Rs m | 2,123 | -6,372 | -33.3% | |
| Profit after tax | Rs m | 10,026 | -368,205 | -2.7% | |
| Gross profit margin | % | 28.8 | 2.6 | 1,099.1% | |
| Effective tax rate | % | 17.5 | 1.3 | 1,379.9% | |
| Net profit margin | % | 18.2 | -32.2 | -56.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 48,228 | 468,855 | 10.3% | |
| Current liabilities | Rs m | 30,376 | 414,764 | 7.3% | |
| Net working cap to sales | % | 32.4 | 4.7 | 684.2% | |
| Current ratio | x | 1.6 | 1.1 | 140.5% | |
| Inventory Days | Days | 68 | 20 | 348.7% | |
| Debtors Days | Days | 86 | 66 | 128.9% | |
| Net fixed assets | Rs m | 64,130 | 129,397 | 49.6% | |
| Share capital | Rs m | 3,000 | 0 | - | |
| Net worth | Rs m | 60,980 | 4,714,905 | 1.3% | |
| Long term debt | Rs m | 15,766 | 1,660,289 | 0.9% | |
| Total assets | Rs m | 121,924 | 7,370,469 | 1.7% | |
| Interest coverage | x | 18.1 | -6.6 | -273.7% | |
| Debt to equity ratio | x | 0.3 | 0.4 | 73.4% | |
| Sales to assets ratio | x | 0.5 | 0.2 | 291.6% | |
| Return on assets | % | 8.8 | -4.1 | -214.7% | |
| Return on equity | % | 16.4 | -7.8 | -210.5% | |
| Return on capital | % | 16.8 | -4.8 | -346.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 11,546 | 408,400 | 2.8% | |
| From Investments | Rs m | -7,138 | 224,362 | -3.2% | |
| From Financial Activity | Rs m | -2,417 | -700,936 | 0.3% | |
| Net Cashflow | Rs m | 2,103 | -67,834 | -3.1% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 72.41 Rs / USD
Compare BIOCON With: MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare BIOCON With: DR. DATSONS LABS SUVEN LIFE SCIENCES ORCHID PHARMA VENUS REMEDIES CADILA HEALTHCARE
Today's Market
Sensex Ends 257 Points Higher, Coal India and UPL Among Top Gainers(Closing)
Indian share markets continued their positive trend during closing hours today and ended their day on a firm note.
Related Views On News
BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)
Jan 25, 2021 | Updated on Jan 25, 2021For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)
Oct 29, 2020 | Updated on Oct 29, 2020For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.
More Views on NewsMost Popular
Intraday Trading for a Living (Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Penny Stock Master Series: The Quest for 10X Profits in 10 Years (Profit Hunter)
Feb 12, 2021This is first of the three part master series. In these editorials, I'll show you how to earn 10X returns from a penny stock portfolio over 10 years.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021 (Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
More
